Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The uropathogenic Escherichia coli (UPEC) early biofilm formation machinery is a coordinated system of surface organelles and assembly pathways essential for the initiation of urinary tract infections (UTIs). The primary component is the Type 1 pilus, which utilizes the FimH adhesin at its distal tip; FimH binds with high affinity to mannosylated uroplakins on the host bladder surface, a process that triggers bacterial invasion and the formation of protective intracellular bacterial communities (IBCs) [Spaulding et al., 2017; Sauer et al., 2019]. This machinery also includes the chaperone-usher pathway (CUP), which is responsible for the folding and transport of pilus subunits across the bacterial envelope, and curli fibers that contribute to the structural integrity of the extracellular biofilm matrix [Hultgren et al., 1993; Greene et al., 2015]. By enabling stable attachment and colonization, this machinery allows UPEC to resist the mechanical flushing of urine and evade host immune detection [Anderson et al., 2003]. Therapeutic strategies targeting this system, such as FimH antagonists (e.g., mannosides like GSK3882347) and pilicides (e.g., FN075), aim to prevent infection by blocking adhesion and assembly rather than killing the bacteria, thereby offering a potential solution to the growing challenge of antibiotic resistance in recurrent UTIs [Totsika et al., 2012; Greene et al., 2015].
The machinery is targeted primarily through the competitive inhibition of the FimH adhesin, which prevents the attachment of Type 1 pili to mannosylated uroplakins on the bladder wall [Spaulding et al., 2017]. Additionally, small-molecule pilicides and curlicides disrupt the chaperone-usher pathway (CUP) by binding to periplasmic chaperones or the outer membrane usher, thereby blocking the assembly of functional fimbriae and curli fibers required for biofilm initiation and structural stability [Greene et al., 2015].
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Uropathogenic Escherichia coli early biofilm formation machinery (UPEC Biofilm Machinery).